Ru­bius chief lays out the first hu­man da­ta on their lead red cell drug in a come­back play. And the stock sky­rock­ets

5 years ago
R&D

Roche drops $1.85B for Gen­Mark's test­ing tech as pan­dem­ic, an­tibi­ot­ic re­sis­tance threats loom

5 years ago
Deals

Backed by In­di­an biosim gi­ant Bio­con, bis­pecifics play­er Bicara de­buts with $40M and sol­id tu­mors on the radar

5 years ago
Financing
Startups

El­e­vate­Bio adds an­oth­er $525M to its war chest as it looks to build on next-gen man­u­fac­tur­ing 'base­cam­p'

5 years ago
Financing
Cell/Gene Tx

On a roll, Re­gen­eron and Sanofi boast pos­i­tive PhI­II OS re­sults in 'no­to­ri­ous­ly' tough can­cer

5 years ago
R&D
Pharma

With hopes for an­ti­bod­ies wan­ing, the NIH will test No­var­tis part­ner's nov­el an­tivi­ral in hos­pi­tal­ized Covid-19 ...

5 years ago
R&D
Coronavirus

Eli Lil­ly touts a 'con­stel­la­tion' of suc­cess­es with their PhII Alzheimer’s study — but dis­ap­point­ing fail­ures ...

5 years ago
Bioregnum
R&D

No­var­tis' wild card block­buster con­tender falls flat; Reg­u­la­to­ry reck­on­ing for check­point drugs looms; and more

5 years ago
Weekly

As­traZeneca ex­pects US vac­cine da­ta ‘soon’ — with 50M dos­es ready by the end of April

5 years ago
Coronavirus

Aveo teams with Bris­tol My­ers af­ter sur­prise FDA ap­proval; Cal­ciMed­ica lines up $21M raise to ad­vance Covid-19 ...

5 years ago
News Briefing

Prometheus and Long­board make the leap to Nas­daq with 9-fig­ure of­fer­ings and are joined by a Fal­con Edge-backed SPAC

5 years ago
Financing

Al­bert Bourla bagged $21M in year marked by gener­ics spin­off, colos­sal R&D ef­fort for Covid-19 vac­cine

5 years ago
People

With Kathy High on board, AskBio makes next lead­er­ship play and se­lects Bay­er's Gu­ru Ra­ma­murthy as fi­nance chief; ...

5 years ago
Peer Review

Lil­ly diss­es Am­gen and Mi­rati as it de­buts new KRAS mol­e­cule

5 years ago
Discovery
Pharma

BAR­DA bets $86M on Con­tra­Fec­t's PhI­II bid against drug-re­sis­tant Staph

5 years ago
Financing

EMA be­gins safe­ty re­view of blue­bird gene ther­a­py fol­low­ing AML case in re­lat­ed ther­a­py

5 years ago
FDA+

Covid-19 roundup: As­traZeneca cuts Q1 vac­cine sup­ply to EU by a third — re­port; Sanofi, Trans­late ush­er an­oth­er ...

5 years ago
Coronavirus

Monte Rosa pulls in $95M to test its 'mol­e­c­u­lar glues,' and the first tar­get is GSPT1

5 years ago
Financing

No­vavax fi­nal re­sults show 96% ef­fi­ca­cy in UK tri­al but plunge to about 50% in South African vari­ant

5 years ago
Coronavirus

Trump’s HHS plant­ed ‘tick­ing time­bomb’ to sun­set thou­sands of regs, law­suit says

5 years ago
FDA+

Ani Phar­ma picks up gener­ic play­er for a cool $210M, tur­bocharg­ing its man­u­fac­tur­ing and R&D wings

5 years ago
Outsourcing
Manufacturing

Covid-19 man­u­fac­tur­ing roundup: Biden dou­bles down on vac­ci­na­tion plan with 100M-dose or­der; BioN­Tech, Pfiz­er ready ...

5 years ago
Coronavirus
Manufacturing

Prometheus up­sizes IPO by 33% ahead of pric­ing; Hu­mani­gen se­cures loan of up to $80M to de­vel­op lenzilum­ab

5 years ago
News Briefing

Gilead part­ner touts an ear­ly snap­shot of its HIV vac­cine ap­proach to a cure — but there's a long path ahead

5 years ago
R&D
First page Previous page 732733734735736737738 Next page Last page
A service from the Financial Times